rating BUY after FTC's approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where scale and product diversity are Increasingly Important. TEVA remains one of our top picks in Spec Pharma, $72 price objective (30% upside). Quick glance at TEVA 7% preferreds 905.50-907 vs $55.16. The